<?xml version='1.0' encoding='utf-8'?>
<document id="31262767"><sentence text="Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects." /><sentence text="SPR741 is a novel polymyxin B derivative, with minimal intrinsic antibacterial activity and reduced nonclinical nephrotoxicity compared to levels with polymyxin B, that interacts with the outer membrane of Gram-negative bacteria, enhancing penetration of coadministered antibiotics"><entity charOffset="18-29" id="DDI-PubMed.31262767.s2.e0" text="polymyxin B" /><entity charOffset="151-162" id="DDI-PubMed.31262767.s2.e1" text="polymyxin B" /><pair ddi="false" e1="DDI-PubMed.31262767.s2.e0" e2="DDI-PubMed.31262767.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31262767.s2.e0" e2="DDI-PubMed.31262767.s2.e1" /></sentence><sentence text=" The safety, tolerability, and pharmacokinetics (PK) of SPR741 were evaluated in two studies, after single and multiple intravenous (i" /><sentence text="v" /><sentence text=") doses in healthy adult subjects and after coadministration with partner antibiotics" /><sentence text=" In the single and multiple ascending-dose study, SPR741 or placebo was administered as a 1-h infusion at single doses of 5 to 800 mg and in multiple doses of 50 to 600 mg every 8 h (q8h) for 14 days" /><sentence text=" In the drug-drug interaction study, a single 400-mg i" /><sentence text="v" /><sentence text=" dose of SPR741 was administered alone and in combination with piperacillin-tazobactam, ceftazidime, and aztreonam"><entity charOffset="63-75" id="DDI-PubMed.31262767.s9.e0" text="piperacillin" /><entity charOffset="76-86" id="DDI-PubMed.31262767.s9.e1" text="tazobactam" /><entity charOffset="88-99" id="DDI-PubMed.31262767.s9.e2" text="ceftazidime" /><entity charOffset="105-114" id="DDI-PubMed.31262767.s9.e3" text="aztreonam" /><pair ddi="false" e1="DDI-PubMed.31262767.s9.e0" e2="DDI-PubMed.31262767.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31262767.s9.e0" e2="DDI-PubMed.31262767.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31262767.s9.e0" e2="DDI-PubMed.31262767.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31262767.s9.e0" e2="DDI-PubMed.31262767.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31262767.s9.e1" e2="DDI-PubMed.31262767.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31262767.s9.e1" e2="DDI-PubMed.31262767.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31262767.s9.e1" e2="DDI-PubMed.31262767.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31262767.s9.e2" e2="DDI-PubMed.31262767.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31262767.s9.e2" e2="DDI-PubMed.31262767.s9.e3" /></sentence><sentence text=" PK parameters for SPR741 and partner antibiotics were determined using noncompartmental analysis" /><sentence text=" After single doses, a dose-linear and proportional increase in mean maximum concentration in plasma (Cmax) and area under the concentration-time curve (AUC) was observed" /><sentence text=" At doses of 100 to 800 mg, &gt;50% of the dose was excreted in the urine in the first 4 h postdose" /><sentence text=" After multiple doses, the mean half-life was 2" /><sentence text="2 h on day 1 and up to 14" /><sentence text="0 h on day 14, with no evidence of accumulation after 14 days of dosing up to 400 mg" /><sentence text=" The PK profile of SPR741 and partner antibiotics was unchanged with coadministration" /><sentence text=" SPR741 was generally well tolerated at doses up to 1,800 mg/day" /><sentence text=" These data support further clinical development of SPR741 for treating serious infections due to resistant bacteria" /><sentence text=" (These studies have been registered at ClinicalTrials" /><sentence text="gov under identifiers NCT03022175 and NCT03376529" /><sentence text=")" /><sentence text="" /></document>